Reed Jobs would rather talk about curing cancer than his last name

Reed Jobs doesn't want to talk about his father. He wants to talk about induced proximity. He wants to talk about dragging a disease-causing protein to the cell's own garbage disposal instead of blocking it. He wants to talk about Quarry, and Azalea, and the $350 million second fund, and the seventeen people now working at Yosemite, and the way AI has stopped being a slide in a pitch deck and started being the engine.

That refusal is the story.

Three years ago, Yosovite was a slide deck and a famous last name. Biotech was crashing out of its pandemic high. Jobs was twenty-something, inheriting a fortune he didn't earn, launching a venture firm in the hardest corner of the hardest industry. The easy narrative wrote itself: rich kid plays biotech tourist. The market would sort him out.

The market didn't. Jobs sorted himself.

Listen to how he describes the model. Yosemite only does oncology — forty percent of biotech, he says, like that's a focus statement rather than a half-measure. They build companies from scratch inside university labs, using philanthropic grants with no strings attached to de-risk ideas before venture dollars touch them. Two of twenty Fund I companies came from grants. A third of the new $350 million goes into homegrown ventures. The rest backs outside founders they want to ride with.

This is not standard venture behavior. Standard venture waits for a deck, a team, a data package. Standard venture does not fund Jennifer Doudna's lab and get Azalea. Standard venture does not sit down with Craig Crews and invent Quarry around a mechanism — induced proximity — that sounds like science fiction until you realize the cell already has the machinery; you just need to bring the target to it.

Jobs knows how that sounds. He uses video-game analogies. He calls ideas "gentle" when they're still living in a professor's notebook. He laughs when asked if he's on a MacBook — "Are you kidding?" — and you believe he means it. The motormouth energy is real. So is the self-deprecation. So is the fact that he's read the papers, tracked the patent cliff, watched AI go from toy to tool in the span of a single fund cycle.

The patent cliff is the structural tailwind nobody planned for. Blockbuster after blockbuster loses protection in the same narrow window. Pharma needs replacements yesterday. They'll pay for assets that look like replacements. Yosemite builds assets that look like replacements. The math is cruel and simple.

AI is the other tailwind. Jobs says it's "a huge part of what Yosemite does now." Not a partner. Not a vendor. Part of the work. Drug discovery, clinical trial design, the grind of matching molecule to mechanism — the firm has folded it into the company-creation assembly line. That's the claim. The proof will be in IND filings and Phase 2 readouts, not in the pitch.

Skepticism has a place here. Company-building ventures have a graveyard of predecessors. The philanthropy-to-venture handoff creates conflict-of-interest questions that "no strings attached" doesn't answer by fiat. Seventeen people is a lot of overhead for a firm that still needs to prove its homegrown companies can survive the valley of death between academic proof-of-concept and pharma-grade data. The patent cliff helps entry; it doesn't guarantee exit.

But Jobs isn't pretending the risk isn't there. He's betting that the combination — oncology focus, company creation, philanthropic de-risking, AI integration, patent-cliff timing — compounds into an edge that pure capital can't buy. He's betting that the best way to find cures is to go make them, not wait for them to float out of a pharma warehouse.

He's also betting that the work speaks louder than the name. So far, it does.